589 results on '"Faries, Mark B."'
Search Results
2. Melanoma sentinel lymph node biopsy in the modern era
3. Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
4. Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial
5. Commentary re PRADO: De-escalation in Melanoma After Neoadjuvant Therapy: When to Cut and When to Cut Back
6. An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma
7. Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II)
8. Sentinel Lymph Node Mapping in Non-small Cell Lung, Colon, and Thyroid Carcinomas
9. Regional Melanoma Therapy: Positive Sentinel Lymph Node
10. Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
11. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
12. Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)
13. Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma
14. Selective Sentinel Node Dissection in Melanoma with Trends and Future Directions.
15. Donald L. Morton Memorial Lecture: the legacy of Donald Morton: past, present and future
16. The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis
17. Surgical Management of Distant Melanoma Metastases
18. Biopsy of the Sentinel Lymph Node
19. Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma
20. A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
21. Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma
22. ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma
23. ASO Visual Abstract: Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in MSLT-II
24. ASO Author Reflections: Minimally Invasive Inguinal Lymphadenectomy, an Incremental Step in the Evolution of the Management of Advanced Melanoma
25. Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
26. Sentinel Lymph Node Biopsy: Indications and Technique
27. Immunohistochemistry for Preferentially Expressed Antigen in Melanoma in the Differential Diagnosis of Melanocytic Lesions of the Nail Apparatus
28. Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma
29. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
30. A Phase III, Multicenter, Randomized Controlled Trial Investigating 1-cm Versus 2-cm Surgical Excision Margins for Stage II Primary Cutaneous Melanoma (MelMarT-II)
31. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease
32. The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes)
33. Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis
34. Systemic Therapy for Melanoma: ASCO Guideline Update
35. Regional Melanoma Therapy: Positive Sentinel Lymph Node
36. Letter Regarding Editorial by Samuel Zagarella
37. Sentinel Lymph Node Biopsy for Melanoma: Buggy Whip or Roller Bearing?
38. Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival
39. Microsatellitosis in Patients with Melanoma
40. Future Perspectives in melanoma research.Meeting report from the "Melanoma Research: a bridge from Naples to the World. Napoli, December 5th-6 th2011".
41. Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era
42. Impact of Time Between Diagnosis and SLNB on Outcomes in Cutaneous Melanoma
43. Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes?
44. Biopsy of the Sentinel Lymph Node
45. Surgical Management of Distant Melanoma Metastases
46. ASO Author Reflections: The Past, Present, and Future of Managing Melanoma Lymph Node Metastases: What the Trials Tell Us
47. Lymph node metastasis in melanoma: a debate on the significance of nodal metastases, conditional survival analysis and clinical trials
48. Data from Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis
49. Figure S4 from Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis
50. Supplementary Figure Legends from Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.